Followers | 3352 |
Posts | 85171 |
Boards Moderated | 5 |
Alias Born | 10/05/2005 |
Sunday, June 28, 2020 2:42:53 PM
Give Me A Follow If You Want To Consistently Find Winners!
Click Here:
https://investorshub.advfn.com/boards/profilea.aspx?user=61470
Please do your own DD...All my posts are my opinion only!
Recent OGEN News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/20/2024 12:00:24 PM
- Oragenics, Inc. Announces NYSE American Acceptance of Plan of Compliance • GlobeNewswire Inc. • 06/20/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 01:27:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2024 12:00:17 PM
- Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer • GlobeNewswire Inc. • 05/22/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 12:00:41 PM
- Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine • GlobeNewswire Inc. • 05/17/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/16/2024 12:00:22 PM
- Oragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002, for Phase II Concussion Trial • GlobeNewswire Inc. • 05/16/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 05:00:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 12:14:33 PM
- Oragenics Partners with Avance Clinical for Phase II Concussion Trial in Australia • GlobeNewswire Inc. • 05/07/2024 12:00:00 PM
- Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards • Business Wire • 04/19/2024 09:50:00 PM
- Oragenics, Inc. Files 10K and Provides Company Update • Business Wire • 04/01/2024 01:05:00 PM
- Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion • Business Wire • 03/18/2024 11:00:00 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 03/06/2024 09:24:29 PM
- Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion • Business Wire • 03/05/2024 12:45:00 PM
- Oragenics Announces Closing of Public Offering • Business Wire • 03/01/2024 09:04:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/29/2024 09:41:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 02:03:04 PM
- Oragenics Announces Pricing of Public Offering • Business Wire • 02/28/2024 02:25:00 AM
- Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses • Edgar (US Regulatory) • 02/27/2024 10:09:12 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/27/2024 10:04:34 PM
- Oragenics Announces Proposed Public Offering • Business Wire • 02/27/2024 09:33:00 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 02/13/2024 01:06:23 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM